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Abstract
Energy intake restriction reduces bone formation both in
protein–energy malnourished children and in under-
nourished rats, and such conditions might cause partial or
irreversible bone loss. Because the use of anti-resorptive
agents in this situation is seemingly limited, we examined
the eﬀect of the anabolic agent, recombinant human
parathyroid hormone (rhPTH(1–84)), on bones in under-
nourished conditions. First, the osteopenic changes of rat
bones with 40% restricted diet for 4 weeks were con-
firmed. Subsequently, another set of the rats were ran-
domized into four groups and studied for 8 weeks: the
freely fed group (control group); the restricted diet, then
freely fed group (restriction–ad libitum group); the
restricted diet–vehicle-treated group (restriction–vehicle
group); and the restricted diet–PTH-treated group
(restriction–PTH group). In the restriction–vehicle group,
total femoral bone mineral density (BMD) was lower
and femoral length was shorter than the control group
by 15·4% and 8·1% respectively (P<0·05). In the
restriction–ad libitum group, these parameters recovered
fully to those of the control group. In the case of
intermittent PTH treatment in the persistent under-
nourished state, the BMD of total femur caught up with
those of the control or the restriction–ad libitum group.
However, the femoral length remained shorter than
those of the other groups. Serum osteocalcin was signifi-
cantly reduced in continuously undernourished rats,
whereas it was elevated in the restriction–PTH group. In
conclusion, BMD of total femur was low in under-
nourished rats. However, it increased after re-feeding
ad libitum or intermittent PTH treatment. We suggest that
rhPTH(1–84) may be a possible therapeutic agent for
ongoing bone loss, especially in patients in a chronically
undernourished condition.
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Introduction
Nowadays, simple undernourishment is not as common as
it was in the past, though conditions inducing cachexia
such as anorexia nervosa and cancer are hard to overlook.
Moreover, the restriction of energy intake is known to
reduce bone formation both in malnourished children and
undernourished rats (Ndiaye et al. 1995a,b). The preva-
lence of low bone mass in anorexia nervosa is about 50%,
and occurs relatively early. In untreated anorexia nervosa
patients, approximately 4–10% of bone loss occurs each
year (Maugars et al. 1996). Furthermore, the aﬀected age
of anorexia nervosa patients overlaps with the period of
peak bone formation. The risk of lifetime fracture in
anorexia nervosa patients is about 2·9 times the norm
(Lucas et al. 1999).
The characteristic bone biochemical marker profiles in
protein–energy malnourished children and in restricted-
fed rats show a reduced level of bone formation marker
(Ndiaye et al. 1995a,b). Osteocalcin levels are also reduced
in anorexia nervosa patients, and an elevation in the
bone resorption markers, deoxypyridinoline (Dpd) or
N-telopeptide (NTX) has been observed in anorexia
nervosa (Grinspoon et al. 1996). Even after the admin-
istration of estrogen or the recovery of near normal body
weight and menstruation, bone loss was only partially
reversed or sometimes bone density is not recovered at all
(Rigotti et al. 1991, Klibanski et al. 1995, Baker et al.
2000). Anti-resorptive agents such as estrogen and bis-
phosphonate, etc. have limited eﬀects on bone changes
related to anorexia nervosa (Klibanski et al. 1995). The
eﬀects of anabolic agents such as parathyroid hormone
(PTH) have not been studied in anorexia nervosa. The
aim in the present study was to determine whether the
intermittent administration of PTH would be eﬀective on
bones in persistently undernourished state.
When PTH is administered as a constant infusion
to normal animals or those in a disease state such as
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hyperparathyroidism, where its level is constantly elevated,
bone is lost, especially at cortical sites (Dobnig & Turner
1997). In contrast, when the hormone is treated in an
intermittent fashion, it has been reported to strongly
increase lumbar bone mineral density (BMD) both in the
normal and the ovariectomized rats (Gunness-Hey &
Hock 1984, Hock et al. 1988, Hori et al. 1988, Liu et al.
1991, Kimmel et al. 1993, Li et al. 1995).
Therefore, it is hypothesized that recombinant human
parathyroid hormone, rhPTH(1–84), a strong anabolic
agent, would restore bone loss related to malnourishment.
To test the eﬀects of rhPTH(1–84) on the bone, an
undernourished osteopenic rat model was established
and the resulting rats were treated with rhPTH(1–84)
intermittently.
Materials and Methods
Animals and food intake
Ten-week-old virgin female Sprague–Dawley rats were
purchased from the Department of Laboratory Animal
Medicine at Yonsei Medical Research Center (Seoul,
Korea). They were housed in a room maintained at
222 C and on 12 h light : 12 h darkness cycles. The
animals were fed in two diﬀerent ways: a freely fed group
and a group that was given 40% of the total amount of the
food intake by the freely fed group. Purina laboratory
rodent chow (Hagribrand Purina Korea Co., Kunsan,
Korea) that contained 1·17% calcium, 0·77% phosphorous,
and 2·6 IU vitamin D per gram was used. The total daily
food intake of the control group was 16·80·3 g during
the first 4 weeks and 17·10·6 g during the last 4 weeks.
Water was provided and animals allowed to drink ad
libitum. All animals were treated in accordance with the
guidelines and regulations for the use and care of animals
of Yonsei University, Seoul, Korea.
Experimental protocols
The animals were weight-matched and divided into six
groups when they were 11 weeks old. There were five to
seven rats per group, and housed two rats per cage. The six
groups were as follows: the 4-week control group, freely
fed for 4 weeks and then sacrificed; the restriction group,
a 40% restricted diet for 4 weeks prior to sacrifice; the
8-week control group where rats were freely fed for
8 weeks then sacrificed; the restriction–ad libitum group,
fed on a 40% restricted diet for the first 4 weeks and then
freely fed for another 4 weeks, then sacrificed; the
restriction–vehicle group, a 40% restricted diet for the
whole 8 weeks and treated with a vehicle during the last
4 weeks, then sacrificed; and the restriction–PTH group,
a 40% restricted diet for 8 weeks and treated with
rhPTH(1–84) during the last 4 weeks, then sacrificed.
rhPTH(1–84) was a gift from the Mogam biotechnology
research institute (Kyungi, Korea), dissolved in 0·9%
normal saline. The restriction–PTH group was treated
daily for 5 days per week with intermittent subcutaneous
injections of 150 µg/kg rhPTH(1–84) per day. The
restriction–vehicle group was injected subcutaneously
with an equivalent volume of 0·9% normal saline at the
same frequency. The detailed protocol used is shown
in Table 1. At the end of the fourth and eighth weeks
of experimental period, the rats were sacrificed by
exsanguinations from the abdominal aorta under
ketamine/xylazine anesthesia. Urine was collected via
metabolic cages over 24 h at timed intervals. Rat blood
samples were taken at timed intervals. Both the collected
urine and serum were stored at 20 C.
Measurement of bone length and density
The right femur lengths were measured using a Mitutoyo
digital caliper (Cole Parmer, Vernon Hills, IL, USA). The
femoral length was measured from the greater trochanter
to intercondylar fossa. The BMD of the excised femurs
was measured by dual energy X-ray absorptiometry
(QDR-4500A, Hologic, Waltham, MA, USA). Triplicate
determinations of the five diﬀerent femurs with
repositioning showed a coeﬃcient of variation of 0·59%.
Osteocalcin and N-telopeptide assays
The osteocalcin concentration of the rat serum was
measured using a rat osteocalcin IRMA assay kit
(Immutopics Inc., San Clemente, CA, USA). The urinary
cross-linked N-telopeptide of type 1 collagen (NTX) was
measured by ELISA (Osteomark, Ostex International,
Seattle, WA, USA). Intra-assay coeﬃcients of variation
Table 1 Experimental protocols. Words shown on the lines
designate the time period where vehicle or PTH was given to the
assigned groups. PTH, rhPTH(1–84) (150 g/kg per day S.C.). Ad
libitum diet is expressed with a bold line and 40% restricted diet
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(CV) for rat osteocalcin were 2·0% at 1·5 ng/ml and
2·3% at 4·3 ng/ml, and the inter-assay CV was 4·0% at
4·0 ng/ml. The intra-assay CVs for NTX were 18% at
26 nM of bone collagen equivalents (BCE), 10% at
439 nM of BCE and 8% at 690 nM of BCE, and the
inter-assay CV for NTX was 6% at 80 nM of BCE. Urine
creatinine was measured by Jaﬀe’s reaction using a Hitachi
747 autoanalyzer (Boehringer Mannheim, Mannheim,
Germany). The intra-assay CV was less than 3·0% for the
urine tests. The groups that were experimented on after
4 weeks were excluded in the measurement of the
biochemical markers.
Cortisol and estradiol assays
The cortisol and estradiol concentration of rat serum were
measured using a rat cortisol RIA assay kit (Beckman
Coulter Inc., Marseille, France) and estradiol RIA assay kit
(Beckman Coulter Inc.). Intra- and inter-assay CVs for
rat cortisol were 2·2% at 407 nmol/l and 4·6% at
416·5 nmol/l respectively, and intra- and inter-assay CVs
for estradiol were 7·2% at 64 pg/ml and 7·9% at 57 pg/ml.
These parameters were only measured in rats killed after
4 weeks.
Statistical analysis
SAS software (6·12 for Windows; SAS, Cary, NC, USA)
was used. The data were expressed as the meansS.D. The
diﬀerences in the BMD and femoral length between the
groups were compared using ANOVA with a Bonferroni’s
multiple group comparison procedure. The data on body
weight, serum osteocalcin and NTX at the timed intervals
were analyzed by repeated measures of the ANOVA
method. The diﬀerence between the osteocalcin and
NTX concentration were analyzed by the Kruskal–Wallis
test and compared with the results of the Mann–Whitney
U test. A P value of less than 0·05 was accepted as
statistically significant.
Results
Changes of body weight
Even after 4 weeks of a restricted diet, body weight
reduction was obvious. After 8 weeks of dietary control,
the animals fed a continuously restricted diet showed 51%
lower body weight than the freely fed control group
(P<0·001, Fig. 1). The initial reduction in body weight
after the restricted diet was recovered to the levels of those
of the control group after 4 weeks of free feeding.
Rat cortisol and estradiol concentrations
Rat cortisol concentrations were significantly reduced after
4 weeks of restricted diet (P<0·05), but there were no
significant diﬀerences in the estradiol levels of freely fed
and undernourished rats (data not shown).
Femoral length
The femoral lengths after 8 weeks in the groups that had
been provided with a 40% restricted diet were significantly
shorter than in the control group, and also shorter than
those of the restriction–ad libitum group (Fig. 2 and Table
2). Four weeks of restricted diet was found to result in a
reduced femoral length. The femoral length reduction was
reversed after feeding ad libitum for a period of 4 weeks to
a similar length as that of the control group. However, the
administration of rhPTH(1–84) had no eﬀect on the
femoral length.
BMD of right femur
BMD decreased after 4 weeks of a restricted diet, but this
was without statistical significance (data not shown),
however, after 8 weeks the BMD was significantly lower
than in the freely fed group (P<0·05, Fig. 3 and Table 2).
The BMD was significantly increased to the level of the
control group in the restriction–PTH group, and also in
the restriction–ad libitum group (P<0·05, Fig. 3 and Table
2). The body weight was positively correlated with the
BMD (r=0·678; P<0·0001).
Serum osteocalcin
Serum osteocalcin concentrations tend to decrease with
increasing age in all groups except the restriction–PTH
group (Table 3). In the restriction–PTH group, the serum
Figure 1 Effects of dietary control and PTH treatment on body
weight. The rats were 11 weeks old when the study started.
Values are presented as meansS.D. Two groups with restricted
diet were injected with vehicle and rhPTH(1–84) respectively from
the 4th week (arrow) to the 8th week. P<0·001, by repeated
measures ANOVA.
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osteocalcin concentration at the eighth week was increased
significantly compared with those of the restriction–
vehicle group (P<0·05, Table 3). In the restriction–ad
libitum group, the serum osteocalcin concentration showed
slight increasing tendency without statistical significance.
NTX levels in 24-h urine
No diﬀerences in the NTX levels in the 24-h urine were
found among the groups (Table 4).
Discussion
In this study, it was found that a restricted diet in growing
rats significantly reduced the body weight, linear growth
and bone formation, and led to low BMD. PTH treatment
significantly improved the BMD and markedly increased
the serum osteocalcin levels even in the group that was
maintained on a restricted diet. In the group with nutri-
tional recovery, both the BMD and the body weight
recovered significantly.
Undernourishment aﬀects the bone metabolism detri-
mentally. Data on energy–protein malnourished children
or undernourished rats has shown that the bone formation
marker osteocalcin is present at reduced levels (Ndiaye
et al. 1995a,b). The calcium content of rat bones that have
suﬀered food restriction of 60% was significantly decreased
(Kalu et al. 1988). The analysis of histomorphometric data
has also shown decreased mineral apposition rate in the
bones of rats fed on energy-restricted diets (Ndiaye et al.
1995a). More astonishingly, anorexia nervosa leads to
partially reversible or sometimes irreversible bone loss,
even after recovering the body weight to a normal level
and the resumption of menstruation, or even after
hormonal replacement therapy (Rigotti et al. 1991,
Klibanski et al. 1995, Baker et al. 2000).
The exact mechanism of bone loss in malnourishment is
not clear. However, several plausible factors have been
proposed. The synthesis of insulin-like growth factor-I
(IGF-I) in the bone as well as in the liver has been found
to be significantly reduced in patients with anorexia
nervosa (Canalis et al. 1989, Counts et al. 1992, Soyka et al.
1999). Especially in anorexia nervosa, estrogen deficiency
Figure 2 Effects of dietary control and PTH treatment on right femoral length at the 8th
week. Each bar represents the meanS.D. *P<0·01 vs ad libitum group or restriction–ad
libitum group.
Table 2 Effects of dietary control and PTH treatment on femoral length and density. Values are meansS.D.
8 weeks
Ad libitum Restriction–ad libitum Restriction–vehicle Restriction–PTH
Parameters
n 6 6 6 6
Femoral length (mm) 35·830·93 34·990·77 32·900·96a 33·170·52a
BMC (g) 0·4790·004 0·4400·004 0·3470·004 0·3970·002
Area (cm2) 1·8210·120 1·7370·006 1·5550·009b 1·6120·038c
BMD (g/cm2) 0·2620·009 0·2540·013 0·2210·016d 0·2470·007
aP<0·001 vs ad libitum and restricted–ad libitum diet groups; bP<0·05 vs ad libitum and restricted–ad libitum diet groups; cP<0·05 vs ad libitum; dP<0·05 vs
ad libitum, restricted–ad libitum diet and restricted diet–PTH-treated groups.
BMC, bone mineral content.
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is one of the contributing factors, because the degree
of bone loss is directly correlated with the duration of
amenorrhea (Biller et al. 1989). Hypercortisolism, present
in about 22% of patients, can also accelerate bone loss
(Lucas et al. 1999). Another worrisome problem might be
an increase in the PTH concentration during food restric-
tion. However, Kalu et al. showed that there was no
significant change or diﬀerence in PTH between freely
fed and restricted-diet rat groups (Kalu et al. 1988).
In undernourished children, it was shown that reduced
osteocalcin levels are fully normalized during nutritional
recovery (Prudhon et al. 1991). However, in conditions
such as anorexia nervosa, several trials aimed at preventing
bone loss in these patients have been conducted in vain.
Neither daily calcium supplements for 23 months nor
estrogen replacement for 1 year increased the BMD in
osteopenic patients with anorexia nervosa (Rigotti et al.
1991, Klibanski et al. 1995). A 6-day trial of low dose
rhIGF-I in women with anorexia nervosa increased the
carboxyl-terminal propeptide of the type 1 procollagen
(PICP) by up to 21·6%, without any evidence of enhanced
bone resorption (Lucas et al. 1999). However, the clinical
application of IGF-I has several limitations, such as short
plasma half-life and some side eﬀects, including hypo-
glycemia and parotid swelling (Guler et al. 1989, Kovacs
et al. 1999). Therefore, another intervention trial to
prevent or treat bone loss associated with this disorder is
warranted.
Intermittent administration of PTH stimulates both
bone formation and resorption and has a greater net
impact on bone formation, resulting in an increase in
bone mass (Gunness-Hey & Hock 1984, Hock et al.
1988, Hori et al. 1988, Liu et al. 1991, Kimmel et al.
1993). The intermittent administration of PTH doubled
the expression of the IGF-I mRNA in the osteoblasts
and stimulated collagen synthesis (Watson et al. 1995,
Urena et al. 1993). Recently, Jilka et al. reported that
PTH suppressed osteoblasts apoptosis, resulting in
prolonged survival of the osteoblasts (Jilka et al. 1999).
Assuming that bone loss in undernourishment may have
a deleterious eﬀect on bone due to the chronic
propensity for fracture, the aim of this study was to
determine whether or not intermittent PTH treatment
could enhance BMD in a malnourished state. The
calorie intake was restricted to about 40% of the
quantity normally consumed by the control rat group in
this experiment. The rationales for reducing the calorie
intake to 40% in this experiment were as follows.
Patients with anorexia nervosa are known to consume
approximately 60% of the daily intake of the controls,
without any significant diﬀerences in the composition of
Figure 3 Effects of dietary control and PTH treatment on BMD of right total femur at the
8th week. Each bar represents meanS.D. *P<0·01 vs ad libitum group and restriction–ad
libitum group and P<0·05 vs restriction–PTH group.
Table 3 Changes of serum osteocalcin. Values are means
S.D. (ng/ml)
Initial Fourth week Eighth week
Ad libitum 53·015·9 48·329·9 34·23·0
Restriction–ad libitum 49·513·9 26·015·1 36·111·9
Restriction–vehicle 55·120·0 39·612·7 30·64·2
Restriction–PTH 50·85·3 35·79·3 59·416·8a
aP<0·05 vs restriction–vehicle group by Mann–Whitney U test.
Table 4 Changes of 24-h urine NTX. Values are meansS.D. (nM
BCE/mM creatinine)
Initial Fourth week Eighth week
Ad libitum 24·87·4 32·014·4 21·07·0
Restriction–ad libitum 32·823·4 32·319·5 25·47·7
Restriction–vehicle 52·044·6 86·7159·9 32·316·4
Restriction–PTH 21·76·8 29·812·8 30·18·3
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protein, fat and carbohydrate (Gwirtsman et al. 1989).
However, in a previous animal study, only 0·9% bone
loss with a concomitant 16·5% decrease in body weight
was observed after restricting the calorie intake to 60%
of that normally consumed by rats for 18 weeks (Banu
et al. 1999).
As expected, intermittent rhPTH(1–84) administration
increased the BMD to the level of the control group
(10·5% vs restriction–vehicle group; P<0·05). Interest-
ingly, nutrition enrichment alone after 4 weeks of dietary
restriction also improved the BMD in rats. Our
observation of an impressive increment in BMD after
intermittent rhPTH(1–84) treatment in a persistently
malnourished state is meaningful, especially with respect
to potential therapies against bone loss.
While the serum osteocalcin concentration was
decreased in accordance with the duration of the restricted
diet and the degree of weight loss, it significantly increased
after intermittent rhPTH(1–84) treatment. Nutritional
enrichment also tends to increase the osteoblastic activity.
However, no significant changes in the urinary bone
resorption marker, NTX, were observed in any group.
The wide distribution of the data and the high coef-
ficient of variation in the urinary NTX concentration
undoubtedly contributed to this result.
Recently, Kronenberg et al., after observing that mice
were missing either the PTH-related peptide (PTHrP) or
the PTH/PTHrP receptor gene, proposed that PTHrP
controls the pace of diﬀerentiation in the growth plate, and
that the Indian hedgehog(Ihh)-PTHrP feedback system
regulates the rate of chondrocyte diﬀerentiation, thereby
balancing the growth and ossification of the long bones
(Kronenberg et al. 1996). Our previous study also showed
that intermittent PTH treatment promoted linear growth
in ovariectomized juvenile rats (Lim et al. 1999). How-
ever, in contrast to the BMD increment, linear growth
did not recover to that of the control group despite
rhPTH(1–84) treatment in the persistent malnourished
state. This suggests that the process of linear growth is a
more complex process that is regulated by many systemic
and local factors under optimal nutritional conditions.
However, more investigation is needed in order to deter-
mine the relationship between linear growth impairment
and nutritional deprivation.
In conclusion, the intermittent administration of
rhPTH(1–84) stimulated bone formation and increased
the BMD in malnourished rats. It is suggested that
rhPTH(1–84) may be a possible therapeutic and preven-
tive agent for ongoing bone loss, especially for those in a
chronically undernourished condition.
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